February 22, 2017 / 9:30 PM / 6 months ago

BRIEF-FDA expands indication for Revlimid in multiple myeloma patients following auto-HSCT

Feb 22 (Reuters) - Celgene Corp:

* FDA expands indication for Revlimid® (lenalidomide) as a maintenance treatment for patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT)

* Celgene Corp - FDA expanded existing indication for revlimid 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy

* Celgene Corp- approval was based on two large studies comparing revlimid maintenance therapy versus no maintenance Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below